267 related articles for article (PubMed ID: 34149737)
21. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
22. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
[TBL] [Abstract][Full Text] [Related]
23. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
Grundy M; Seedhouse C; Russell NH; Pallis M
BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
[TBL] [Abstract][Full Text] [Related]
24. Involvement of macrophage-derived exosomes in abdominal aortic aneurysms development.
Wang Y; Jia L; Xie Y; Cai Z; Liu Z; Shen J; Lu Y; Wang Y; Su S; Ma Y; Xiang M
Atherosclerosis; 2019 Oct; 289():64-72. PubMed ID: 31479773
[TBL] [Abstract][Full Text] [Related]
25. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
Shmeeda H; Tzemach D; Mak L; Gabizon A
J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
[TBL] [Abstract][Full Text] [Related]
26. Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity.
Ho KW; Chen IU; Cheng YA; Liao TY; Liu ES; Chen HJ; Lu YC; Su YC; Roffler SR; Huang BC; Liu HJ; Huang MY; Chen CY; Cheng TL
J Nanobiotechnology; 2021 Jan; 19(1):16. PubMed ID: 33422061
[TBL] [Abstract][Full Text] [Related]
27. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
[TBL] [Abstract][Full Text] [Related]
28. Exosome production and its regulation of EGFR during wound healing in renal tubular cells.
Zhou X; Zhang W; Yao Q; Zhang H; Dong G; Zhang M; Liu Y; Chen JK; Dong Z
Am J Physiol Renal Physiol; 2017 Jun; 312(6):F963-F970. PubMed ID: 28356285
[TBL] [Abstract][Full Text] [Related]
29. Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells.
Wu ZX; Yang Y; Wang G; Wang JQ; Teng QX; Sun L; Lei ZN; Lin L; Chen ZS; Zou C
Cancer Sci; 2020 Aug; 111(8):2872-2882. PubMed ID: 32478948
[TBL] [Abstract][Full Text] [Related]
30. A nanounit strategy reverses immune suppression of exosomal PD-L1 and is associated with enhanced ferroptosis.
Wang G; Xie L; Li B; Sang W; Yan J; Li J; Tian H; Li W; Zhang Z; Tian Y; Dai Y
Nat Commun; 2021 Sep; 12(1):5733. PubMed ID: 34593794
[TBL] [Abstract][Full Text] [Related]
31. TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.
Erriquez J; Becco P; Olivero M; Ponzone R; Maggiorotto F; Ferrero A; Scalzo MS; Canuto EM; Sapino A; Verdun di Cantogno L; Bruna P; Aglietta M; Di Renzo MF; Valabrega G
Gynecol Oncol; 2015 Sep; 138(3):627-33. PubMed ID: 26100858
[TBL] [Abstract][Full Text] [Related]
32. Exosomal DNMT1 mediates cisplatin resistance in ovarian cancer.
Cao YL; Zhuang T; Xing BH; Li N; Li Q
Cell Biochem Funct; 2017 Aug; 35(6):296-303. PubMed ID: 28791708
[TBL] [Abstract][Full Text] [Related]
33. Leukemia-derived exosomes induced IL-8 production in bone marrow stromal cells to protect the leukemia cells against chemotherapy.
Chen T; Zhang G; Kong L; Xu S; Wang Y; Dong M
Life Sci; 2019 Mar; 221():187-195. PubMed ID: 30716336
[TBL] [Abstract][Full Text] [Related]
34. Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin.
Federici C; Petrucci F; Caimi S; Cesolini A; Logozzi M; Borghi M; D'Ilio S; Lugini L; Violante N; Azzarito T; Majorani C; Brambilla D; Fais S
PLoS One; 2014; 9(2):e88193. PubMed ID: 24516610
[TBL] [Abstract][Full Text] [Related]
35. Binding and inhibition of drug transport proteins by heparin: a potential drug transporter modulator capable of reducing multidrug resistance in human cancer cells.
Chen Y; Scully M; Petralia G; Kakkar A
Cancer Biol Ther; 2014 Jan; 15(1):135-45. PubMed ID: 24253450
[TBL] [Abstract][Full Text] [Related]
36. Exosome secretion is a key pathway for clearance of pathological TDP-43.
Iguchi Y; Eid L; Parent M; Soucy G; Bareil C; Riku Y; Kawai K; Takagi S; Yoshida M; Katsuno M; Sobue G; Julien JP
Brain; 2016 Dec; 139(Pt 12):3187-3201. PubMed ID: 27679482
[TBL] [Abstract][Full Text] [Related]
37. Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
Martínková J; Bláha M; Kubeček O; Maláková J; Špaček J; Bezouška J; Krulichová IS; Filip S
Cancer Chemother Pharmacol; 2016 Feb; 77(2):429-37. PubMed ID: 26678853
[TBL] [Abstract][Full Text] [Related]
38. Quinacrine and curcumin synergistically increased the breast cancer stem cells death by inhibiting ABCG2 and modulating DNA damage repair pathway.
Nayak D; Tripathi N; Kathuria D; Siddharth S; Nayak A; Bharatam PV; Kundu C
Int J Biochem Cell Biol; 2020 Feb; 119():105682. PubMed ID: 31877386
[TBL] [Abstract][Full Text] [Related]
39. The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1--deficient ovarian tumors and can be exploited to improve treatment response in a mouse model.
Mantia-Smaldone G; Ronner L; Blair A; Gamerman V; Morse C; Orsulic S; Rubin S; Gimotty P; Adams S
Gynecol Oncol; 2014 Jun; 133(3):584-90. PubMed ID: 24680909
[TBL] [Abstract][Full Text] [Related]
40. Snail1-dependent cancer-associated fibroblasts induce epithelial-mesenchymal transition in lung cancer cells via exosomes.
You J; Li M; Cao LM; Gu QH; Deng PB; Tan Y; Hu CP
QJM; 2019 Aug; 112(8):581-590. PubMed ID: 31106370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
